AzTrials
AzTrials

Musculoskeletal DiseasesNutririskNCT05546541

Epidemiology and Nutrition

An observational study of Musculoskeletal Diseases and Osteoarthritis, Knee, run by I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The general purpose of this study is to evaluate the relation between the nutritional status of patients, the features of the orthobiologics products used for patients' treatment and the clinical outcomes after one-step conservative regenerative treatment for knee osteoarthritis. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
How many people
88 participants
Where
1 siteItaly
Study dates
29 Sep 2021to 30 Jun 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Patients affected by knee osteoarthritis undergoing conservative regenerative medicine procedures with autologous material at IRCCS Istituto Ortopedico Galeazzi and participating to the observational study "REGAIN" will be enrolled for this study: 88 patients will be needed: 1. 22 subjects with body mass index (BMI) considered normal weight (≥18.5 and ≤25) undergo to Platelet-Rich Plasma (PRP) treatment; 2. 22 subjects with BMI>25 undergo to PRP treatment; 3. 22 subjects with BMI ≥18.5 and ≤25 undergo to microfragmented adipose tissue treatment; 4. 22 subjects with BMI >25 undergo to microfragmented adipose tissue treatment.

Who may be able to join

  • males and females ≥18 and ≤ 65 years;
  • presence of knee osteoarthritis;
  • indication to regenerative medicine treatments PRP or microfragmented adipose treatment;
  • participation to the observational study "REGAIN";
  • patients with BMI ≥18.5;
  • signature of Informed Consent for the study.

Who cannot join

  • patients with BMI <18.5;
  • patients who are not able to comply with the study schedule.

Trial locations and contacts

1 site in 1 country.

Italy1 site, 1 recruiting
  • IRCCS Galeazzi orthopaedic institute

    Milan, Italia

    Elena Cittera, 0039 02 66214057, mailto:elena.cittera@grupposandonato.it

    Paola De Luca, post doc researcher

    Recruiting

Other trials in Italy

About this study

Official title: Nutrition as a Risk Factor and Predictor of the Outcome of Orthobiological Treatments for Knee Osteoarthritis

The general purpose of this study is to evaluate the relation between the nutritional status of patients, the features of the orthobiologics products used for patients' treatment and the clinical outcomes after one-step conservative regenerative treatment for knee osteoarthritis.

Read the detailed description

The general purpose of this monocentric, observational with additional procedure (extra routine blood sampling, questionnaires and measurement of Nutritional status), prospective and non-controlled study is to evaluate the relation between the nutritional status of patients, the features of the orthobiologics products used for patients' treatment and the clinical outcomes after one-step conservative regenerative treatment (Platelete rich plasma and micro-fragmented adipose tissue injections) for knee osteoarthritis.The primary outcome of the study will be the identification of the proportion of responders and non-responders patients to the orthobiologic treatment (according to OMERACT-OARSI criteria) at 6-month follow-up. Another primary outcome will be the nutritional status identification of the same patients.

For these purposes the responder or non-responder patients will be identified based on the results of the Visual Analogue Scale (VAS) [the score is determined by measuring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100; a higher score indicates greater pain intensity no pain (0-4 mm), mild pain (5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm)], Tegner-Lysholm Activity Scale and Knee Injury (Scores range from 0=worse disability to 100=less disability) and Osteoarthritis Outcome score (KOOS) (the score is a percentage score from 0 to 100, 0 representing extreme problems and 100 representing no problems) according to the parameters established by Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) and Osteoarthritis Research Society International (OARSI) [they cannot be represented by a range of values]. The secondary outcomes of the study will be:

  • the identification of the proportion of responders and non-responders patients to the orthobiologic treatment (according to OMERACT-OARSI criteria) at 2 and 12-month follow-up and of their related nutritional status;
  • the characterization of the orthobiologic products used for the patient's treatment.

After the ethics committee approval, patients meeting the inclusion criteria undergoing conservative knee regenerative medicine treatments with orthobiologics and participating to the observational study "REGAIN" will be enrolled into the study. The PROMs will be completed by patients based on their clinical condition and on the specific treatment they will receive at the REGAIN Center. The aforementioned PROMs include but are not limited to:

  • VAS, Tegner-Lysholm Activity Scale, KOOS. Patients will be asked to filled the PROMs at the time of the enrollment (before the treatment) and then at 2, 6 and 12 months after the treatment.

Blood and nutritional information will be collected only the day of the treatment to allow for evaluation of the possible association between patients' characteristics and treatment outcomes. Blood sampling will be performed to carry out the following laboratory analysis, in detail: complete blood count (cell number/dl), blood glucose (mg/dl), hemoglobin A1C (HbA1c) (mmol/mol), creatinine (mg/dl), Glutamic Oxaloacetic Transaminase (GOT) and Glutamic-Pyruvic Transaminase (GPT) (U/L), C reactive protein (mg/dl), triglycerides (mg/dl), total cholesterol(mg/dl), HDL(mg/dl).

In particular, for patients undergoing a Platelet Rich Plasma (PRP) treatment, a blood sample is already routinely harvested and therefore only an extra test tube will be added to test blood glucose (mg/dl), hemoglobin A1C (HbA1c) (mmol/mol), creatinine (mg/dl), GOT and GPT transaminases (U/L), C reactive protein (mg/dl), triglycerides (mg/dl), total cholesterol(mg/dl), HDL(mg/dl). For patients undergoing a treatment with microfragmented adipose tissue, an ad hoc blood collection will be carried out by filling two test tubes.

Nutritional information include anthropometric measurements, diet history and food consumption questionnaire (24h recall, "How much do i really eat?", Italian Mediterranea Index, anamnesi). Anthropometric measurements include weight (kg) and height (m), waist circumference (cm), arm circumference measurements (cm), biceps, triceps, subscapular and suprailiac folds measurement (mm) (plicometry) through the use of the skinfolder. It should be noted that the skinfolder is only one of the tools used to evaluate the patient's nutritional status, without diagnostic purposes and without the will to investigate anything about the device.

Concerning the orthobiologics characterization, PRP and microfragmented adipose tissue will undergo to different evaluations as per the observational study protocol "REGAIN".

In addition, for the purpose of this study, isolation and characterization of extracellular vesicles derived from PRP and micro fragmented adipose tissue will be performed, in order to deepen the orthobiologic characterization. The following techniques will be applied, where appropriate:

  • Count and identification of cells from PRP and microfragmented adipose tissue (hemacytometer, nucleocounter, flow cytometry);
  • Extracellular vesicle isolation, count and dimensional analysis (ultracentrifuge, Nanosights);
  • Extracellular vesicle marker identification (flow cytometry).

These data will be analyzed for their possible association with nutritional status of the patient and clinical outcomes.

Regardless the specific protocol or investigation, the analysis will not include genomic DNA or diagnostic analysis. All samples (blood and tissues) will be analyzed at Istituto Ortopedico Galeazzi and destroyed at the end of the study. Total duration of this study is of 36 months after approval of Ethical Committee.

Medical subject headings
Musculoskeletal Diseases, Osteoarthritis, Knee

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT05546541
Study groupRoleWhat they receive
subjects normal weight undergo to PRP treatmentsubjects with body mass index (BMI) considered normal weight (≥18.5 and ≤25) undergo to Platelet-Rich Plasma (PRP) treatment.
subjects overweight undergo to PRP treatmentsubjects with BMI values that exceed the normal weight range (BMI>25) undergo to PRP treatment.
subjects with normal weight undergo to microfragmented adipose tissue treatmentsubjects with BMI within the considered normal weight range (≥18.5 e ≤25) and undergo to microfragmented adipose tissue treatment.
subjects overweight undergo to microfragmented adipose tissue treatmentsubjects with BMI values that exceed the normal weight range undergo to microfragmented adipose tissue treatment. (BMI>25).

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 6 months follow-up, responders and not responders

    Identification of the proportion of responders and non-responders patients to the orthobiologic treatment (according to OMERACT-OARSI criteria) at 6-month follow-up.

    Measured: 6 months after treatment

  2. Identification of the nutritional status of patients: Complete blood count

    Complete blood count (cell number/dl)

    Measured: 10 minutes before the treatment

  3. Identification of the nutritional status of patients: Blood glucose

    Blood glucose (mg/dl) measurement

    Measured: 10 minutes before the treatment

  4. Identification of the nutritional status of patients: blood Hemoglobin A1C (HbA1c)

    Hemoglobin A1C (HbA1c) (mmol/mol) measurement

    Measured: 10 minutes before the treatment

  5. Identification of the nutritional status of patients: blood creatinine

    Creatinine (mg/dl) measurement

    Measured: 10 minutes before the treatment

  6. Identification of the nutritional status of patients: blood Glutamic-Oxaloacetic Transaminase GOT (U/L)

    Glutamic-Oxaloacetic Transaminase GOT (U/L) measurement

    Measured: 10 minutes before the treatment

  7. Identification of the nutritional status of patients: blood Glutamate Pyruvate Transaminase GPT

    Glutamate Pyruvate Transaminase GPT (U/L) measurement

    Measured: 10 minutes before the treatment

  8. Identification of the nutritional status of patients: blood C reactive protein

    C reactive protein (mg/dl) measurement

    Measured: 10 minutes before the treatment

  9. Identification of the nutritional status of patients: blood Triglycerides

    Triglycerides (mg/dl) measurement

    Measured: 10 minutes before the treatment

  10. Identification of the nutritional status of patients: blood total cholesterol

    Total cholesterol (mg/dl) measurement

    Measured: 10 minutes before the treatment

  11. Identification of the nutritional status of patients: blood High Density Lipoprotein HDL

    High Density Lipoprotein HDL (mg/dl) measurement

    Measured: 10 minutes before the treatment

  12. Anthropometric measurement: weight

    weight (kg) measurement

    Measured: 10 minutes before the treatment

  13. Anthropometric measurement: height

    height (m) measurement

    Measured: 10 minutes before the treatment

  14. Anthropometric measurement: waist circumference

    waist circumference (cm) measurement

    Measured: 10 minutes before the treatment

  15. Anthropometric measurement: arm circumference measurements

    arm circumference measurements (cm)

    Measured: 10 minutes before the treatment

  16. Anthropometric measurement: biceps folds measurement

    biceps folds measurement (mm)

    Measured: 10 minutes before the treatment

  17. Anthropometric measurement: triceps folds measurement

    triceps folds measurement (mm)

    Measured: 10 minutes before the treatment

  18. Anthropometric measurement: subscapular folds measurement

    subscapular folds measurement (mm)

    Measured: 10 minutes before the treatment

  19. Anthropometric measurement: suprailiac folds measurement

    suprailiac folds measurement (mm)

    Measured: 10 minutes before the treatment

Secondary outcomes (3)
  1. 2 months follow-up, responders and not responders

    The identification of the proportion of responders and non-responders patients to the orthobiologic treatment (according to OMERACT-OARSI criteria) at 2 months follow-up

    Measured: 2 months after treatment

  2. 12 months follow-up, responders and not responders

    The identification of the proportion of responders and non-responders patients to the orthobiologic treatment (according to OMERACT-OARSI criteria) at 12 months follow-up

    Measured: 12 months after treatment

  3. The characterization of the orthobiologic products.

    The characterization of the orthobiologic products used for the patient's treatment that include isolation and characterization of extracellular vesicles derived from PRP and micro fragmented adipose tissue.

    Measured: 15 minutes after the treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Sep 2022
  2. Study start29 Sep 2021
  3. Primary completion30 Jun 2023 (estimated)
  4. Study completion30 Jun 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
88 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05546541
Sponsor's protocol ID
Nutririsk
Acronym
Nutririsk
Status last verified
Sep 2022
First submitted
28 Dec 2021
Last updated
21 Sep 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Musculoskeletal Diseases and Osteoarthritis, Knee, run by I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 21 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

6 months follow-up, responders and not responders (time frame: 6 months after treatment). The study lists 19 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in